FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2016009621> ?p ?o ?g. }

• W2016009621 endingPage "375" @default.
• W2016009621 startingPage "375" @default.
• W2016009621 abstract "Development of anaplastic lymphoma kinase (ALK) inhibitors and molecular diagnosis in ALK rearrangement-positive lung cancer Eiji Iwama,1,2 Isamu Okamoto,3 Taishi Harada,2 Koichi Takayama,2 Yoichi Nakanishi2,3 1Department of Comprehensive Clinical Oncology, Faculty of Medical Sciences, Kyushu University, 2Research Institute for Diseases of the Chest, Graduate School of Medical Sciences, Kyushu University, 3Center for Clinical and Translational Research, Kyushu University Hospital, Fukuoka, Japan Abstract: The fusion of echinoderm microtubule-associated protein-like 4 with anaplastic lymphoma kinase (ALK) was identified as a transforming gene for lung cancer in 2007. This genetic rearrangement accounts for 2%–5% of non-small-cell lung cancer (NSCLC) cases, occurring predominantly in younger individuals with adenocarcinoma who are never- or light smokers. A small-molecule tyrosine-kinase inhibitor of ALK, crizotinib, was rapidly approved by the US Food and Drug Administration on the basis of its pronounced clinical activity in patients with ALK rearrangement-positive NSCLC. Next-generation ALK inhibitors, such as alectinib, LDK378, and AP26113, are also being developed in ongoing clinical trials. In addition, the improvement and validation of methods for the detection of ALK rearrangement in NSCLC patients will be key to the optimal clinical use of ALK inhibitors. We here summarize recent progress in the development of new ALK inhibitors and in the molecular diagnosis of ALK rearrangement-positive NSCLC. Keywords: ALK, rearrangement, NSCLC, ALK inhibitor, targeted therapy, diagnosis" @default.
• W2016009621 created "2016-06-24" @default.
• W2016009621 creator A5003016795 @default.
• W2016009621 creator A5011258855 @default.
• W2016009621 creator A5035882975 @default.
• W2016009621 creator A5044370173 @default.
• W2016009621 creator A5072724155 @default.
• W2016009621 date "2014-03-01" @default.
• W2016009621 modified "2023-10-18" @default.
• W2016009621 title "Development of anaplastic lymphoma kinase (ALK) inhibitors and molecular diagnosis in ALK rearrangement-positive lung cancer" @default.
• W2016009621 cites W112165853 @default.
• W2016009621 cites W1719751125 @default.
• W2016009621 cites W1968407547 @default.
• W2016009621 cites W1970819482 @default.
• W2016009621 cites W1972309243 @default.
• W2016009621 cites W1980497534 @default.
• W2016009621 cites W1981989535 @default.
• W2016009621 cites W1986552598 @default.
• W2016009621 cites W1997476230 @default.
• W2016009621 cites W1998371249 @default.
• W2016009621 cites W2000397789 @default.
• W2016009621 cites W2007217902 @default.
• W2016009621 cites W2008167816 @default.
• W2016009621 cites W2016710415 @default.
• W2016009621 cites W2026853353 @default.
• W2016009621 cites W2031159738 @default.
• W2016009621 cites W2037168012 @default.
• W2016009621 cites W2038056960 @default.
• W2016009621 cites W2038473057 @default.
• W2016009621 cites W2038586807 @default.
• W2016009621 cites W2043696829 @default.
• W2016009621 cites W2050249255 @default.
• W2016009621 cites W2053541213 @default.
• W2016009621 cites W2055402151 @default.
• W2016009621 cites W2066417528 @default.
• W2016009621 cites W2069646737 @default.
• W2016009621 cites W2071378494 @default.
• W2016009621 cites W2080992857 @default.
• W2016009621 cites W2092036762 @default.
• W2016009621 cites W2094903176 @default.
• W2016009621 cites W2096156234 @default.
• W2016009621 cites W2096786080 @default.
• W2016009621 cites W2098599074 @default.
• W2016009621 cites W2104830962 @default.
• W2016009621 cites W2106197862 @default.
• W2016009621 cites W2113327188 @default.
• W2016009621 cites W2121005606 @default.
• W2016009621 cites W2123727052 @default.
• W2016009621 cites W2125735484 @default.
• W2016009621 cites W2129360604 @default.
• W2016009621 cites W2132157071 @default.
• W2016009621 cites W2134607826 @default.
• W2016009621 cites W2134787029 @default.
• W2016009621 cites W2135329354 @default.
• W2016009621 cites W2136549983 @default.
• W2016009621 cites W2139110945 @default.
• W2016009621 cites W2140333474 @default.
• W2016009621 cites W2149152398 @default.
• W2016009621 cites W2150424194 @default.
• W2016009621 cites W2154149901 @default.
• W2016009621 cites W2154905832 @default.
• W2016009621 cites W2167592581 @default.
• W2016009621 cites W2168106545 @default.
• W2016009621 cites W2170144893 @default.
• W2016009621 cites W2240169541 @default.
• W2016009621 cites W2415261641 @default.
• W2016009621 cites W2596888329 @default.
• W2016009621 cites W2611771842 @default.
• W2016009621 doi "https://doi.org/10.2147/ott.s38868" @default.
• W2016009621 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3949762" @default.
• W2016009621 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24623980" @default.
• W2016009621 hasPublicationYear "2014" @default.
• W2016009621 type Work @default.
• W2016009621 sameAs 2016009621 @default.
• W2016009621 citedByCount "17" @default.
• W2016009621 countsByYear W20160096212015 @default.
• W2016009621 countsByYear W20160096212016 @default.
• W2016009621 countsByYear W20160096212017 @default.
• W2016009621 countsByYear W20160096212018 @default.
• W2016009621 countsByYear W20160096212019 @default.
• W2016009621 countsByYear W20160096212020 @default.
• W2016009621 countsByYear W20160096212022 @default.
• W2016009621 countsByYear W20160096212023 @default.
• W2016009621 crossrefType "journal-article" @default.
• W2016009621 hasAuthorship W2016009621A5003016795 @default.
• W2016009621 hasAuthorship W2016009621A5011258855 @default.
• W2016009621 hasAuthorship W2016009621A5035882975 @default.
• W2016009621 hasAuthorship W2016009621A5044370173 @default.
• W2016009621 hasAuthorship W2016009621A5072724155 @default.
• W2016009621 hasBestOaLocation W20160096211 @default.
• W2016009621 hasConcept C104317684 @default.
• W2016009621 hasConcept C117643217 @default.
• W2016009621 hasConcept C121608353 @default.
• W2016009621 hasConcept C126322002 @default.
• W2016009621 hasConcept C143998085 @default.
• W2016009621 hasConcept C2776232967 @default.
• W2016009621 hasConcept C2776256026 @default.
• W2016009621 hasConcept C2778347629 @default.

• next